Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK2 | P53671 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30228202 | 0.92 | GPR119 (0.45) | LIMK2GPR119HPGDKDM4EPKM | |
| SCHEMBL1401260 | 0.88 | HPGD (0.53) | LIMK2GPR119HPGDKDM4EPKM | |
| SCHEMBL5570674 | 0.86 | HPGD (0.51) | LIMK2GPR119HPGDKDM4EPKM | |
| SCHEMBL7986517 | 0.85 | LIMK2 (0.48) | LIMK2GPR119HPGDKDM4EPKM | |
| SCHEMBL5135436 | 0.83 | HPGD (0.44) | LIMK2GPR119HPGDKDM4EPKM | |
| SCHEMBL18428924 | 0.83 | HPGD (0.46) | LIMK2GPR119HPGDKDM4EPKM | |
| SCHEMBL25580911 | 0.82 | HPGD (0.48) | LIMK2GPR119HPGDKDM4EPKM | |
| SCHEMBL27391556 | 0.81 | HPGD (0.50) | LIMK2GPR119HPGDKDM4EPKM | |
| SCHEMBL14222486 | 0.81 | ACHE (0.46) | GPR119HPGDKDM4EPKMFAAH | |
| SCHEMBL6152127 | 0.81 | HPGD (0.49) | LIMK2GPR119HPGDKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-29 | — | — | US | disclosed |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | MCHR1, MCHR2, MC5R | LIMK2 4076/4885GPR119 8/4885HPGD 1286/4885 |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | LIMK2 455/4885GPR119 1715/4885HPGD 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.